Boston-based AOA Dx has raised new capital and is preparing to scale, including with its first clinical trial for an early detection test for ovarian cancer.
Yet, the company’s next stage of growth will be focused in Colorado.
The biotech startup announced an oversubscribed $17 million round Wednesday morning led by Good Growth Capital. Other investors in the round included RH Capital, Y Combinator and FemHealth Ventures, as well as diagnostic investors like Labcorp Venture Fund.
This brings…
Source link
